Novartis Sees Reimbursement Advantage For PCSK9 Launch
Executive Summary
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
You may also be interested in...
Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key
Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.
Esperion Aiming For 50% Commercial Coverage For Nexletol
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.
Need a specific report? 1000+ reports available
Buy Reports